Literature DB >> 16112644

Effects of SUMO-1 upon Epstein-Barr virus BZLF1 function and BMRF1 expression.

Amy L Adamson1.   

Abstract

Epstein-Barr virus (EBV) is a human herpesvirus that has infected at least 90% of the world population. This very successful virus causes infectious mononucleosis and is associated with many different types of cancer. The EBV BZLF1 protein is a transcription factor that has also been shown to interact with many host cell proteins and pathways. BZLF1 (Z) is tagged by the small ubiquitin-related modifier-1 (SUMO-1) protein. Here, we present studies of the functional consequences of SUMO-1 modification of Z. We found that SUMO-1 modification of Z has no apparent effect upon the stability and localization of the Z protein. We did find, however, that SUMO-1 modification decreases the transactivation activity of Z on specific promoters. In addition, when SUMO-1 is supplied to cells when lytic replication is induced, EBV BMRF1 levels greatly increase, suggesting that SUMO-1 enhances EBV lytic replication. Therefore, SUMO-1 modification of proteins appears to have an important role in EBV lytic replication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112644     DOI: 10.1016/j.bbrc.2005.08.036

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

Review 1.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  HPV E6 proteins target Ubc9, the SUMO conjugating enzyme.

Authors:  Phillip R Heaton; Adeline F Deyrieux; Xue-Lin Bian; Van G Wilson
Journal:  Virus Res       Date:  2011-04-12       Impact factor: 3.303

3.  The Epstein-Barr virus LF2 protein inhibits viral replication.

Authors:  Michael A Calderwood; Amy M Holthaus; Eric Johannsen
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

4.  Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase.

Authors:  Stacy R Hagemeier; Sarah J Dickerson; Qiao Meng; Xianming Yu; Janet E Mertz; Shannon C Kenney
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

5.  LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Authors:  Gretchen L Bentz; Charles Randall Moss; Christopher B Whitehurst; Cary A Moody; Joseph S Pagano
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

6.  Sumoylation of the Carboxy-Terminal of Human Cytomegalovirus DNA Polymerase Processivity Factor UL44 Attenuates Viral DNA Replication.

Authors:  Jun Chen; Guanlie Li; Haiqing He; Xin Li; Wenjing Niu; Di Cao; Ao Shen
Journal:  Front Microbiol       Date:  2021-04-21       Impact factor: 5.640

7.  Functional interaction between human herpesvirus 6 immediate-early 2 protein and ubiquitin-conjugating enzyme 9 in the absence of sumoylation.

Authors:  Andru Tomoiu; Annie Gravel; Robert M Tanguay; Louis Flamand
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

8.  Transcriptional repression by sumoylation of Epstein-Barr virus BZLF1 protein correlates with association of histone deacetylase.

Authors:  Takayuki Murata; Naoe Hotta; Shigenori Toyama; Sanae Nakayama; Shigeki Chiba; Hiroki Isomura; Takayuki Ohshima; Teru Kanda; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2010-06-01       Impact factor: 5.157

9.  Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta.

Authors:  Mengmeng Zhao; Asuka Nanbo; David Becnel; Zhiqiang Qin; Gilbert F Morris; Li Li; Zhen Lin
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

10.  Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.

Authors:  Peter Garcia; Abigail Harrod; Shruti Jha; Jessica Jenkins; Alex Barnhill; Holden Lee; Merritt Thompson; Jordan Pringle Williams; James Barefield; Ashton Mckinnon; Persia Suarez; Ananya Shah; Angela J Lowrey; Gretchen L Bentz
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.